ADIL

Adial Pharmaceuticals, Inc. NASDAQ Listed Jul 27, 2018

Healthcare ·Biotechnology ·US · adialpharma.com

$1.42

Mkt Cap $1.4M

52w Low $1.38 0.2% of range 52w High $19.00

50d MA $1.78 200d MA $6.32

P/E (TTM) -0.1x

EV/EBITDA 0.3x

P/B 0.2x

Debt/Equity 0.0x

ROE -151.2%

P/FCF -0.6x

RSI (14) —

ATR (14) —

Beta 1.40

50d MA $1.78

200d MA $6.32

Avg Volume 110.0K

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

SIC Code

2834

CIK (SEC)

1513525

Phone

434 422 9800

1180 Seminole Trail · Charlottesville, VA 22901 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 10, 2026	AMC	-2.10	-1.81	+13.8%	1.83	+3.8%	+7.7%	-5.1%	+4.8%	-5.6%	+2.2%	—
Nov 13, 2025	AMC	-2.25	-2.00	+11.1%	8.00	-3.1%	+3.1%	-6.1%	+0.0%	+3.2%	-6.2%	—
Aug 13, 2025	AMC	-0.22	-0.18	+18.2%	10.00	-5.0%	-2.5%	+0.0%	-2.6%	-2.6%	+0.0%	—
May 14, 2025	AMC	-0.50	-0.34	+32.0%	16.25	+4.6%	+1.5%	+0.0%	+6.1%	+4.3%	-2.7%	—
Mar 4, 2025	AMC	-0.38	-0.15	+60.5%	18.75	-1.3%	+2.7%	-2.6%	+0.0%	-4.0%	-12.5%	—
Nov 13, 2024	AMC	-0.50	-0.38	+24.0%	24.75	+11.1%	+15.2%	-7.0%	-4.7%	+0.0%	+1.0%	—
Aug 13, 2024	AMC	-0.39	-0.59	-51.3%	24.25	-2.1%	+0.0%	+0.0%	+0.0%	+1.0%	+0.0%	—
May 14, 2024	AMC	-0.51	-0.68	-33.3%	36.00	-4.9%	-1.4%	-0.7%	+9.9%	-3.2%	-6.7%	—
Apr 4, 2024	AMC	-0.76	-1.35	-77.6%	30.50	-5.7%	-4.9%	-2.6%	+0.0%	+106.2%	+27.9%	—
Nov 14, 2023	AMC	-1.14	-1.14	+0.0%	54.00	+0.0%	-1.9%	-3.8%	+2.9%	-1.9%	+5.8%	—
Aug 21, 2023	AMC	-1.50	-1.33	+11.3%	83.75	-0.3%	-1.8%	+3.3%	-0.3%	+1.2%	-2.6%	—
May 12, 2023	AMC	-3.50	-2.75	+21.4%	187.50	+6.7%	+6.7%	+0.0%	+3.1%	-3.0%	+0.0%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Sep 30	Maxim Group	Upgrade	Hold → Buy	—	$8.25	$8.75	+6.1%	+6.1%	+5.7%	+8.1%	+0.0%	+0.0%
Jul 11	Brookline Capital	Maintains	Buy → Buy	—	$125.00	$137.50	+10.0%	+95.0%	-15.4%	-12.1%	-3.4%	+3.6%
Aug 17	Maxim Group	Downgrade	Buy → Hold	—	$356.25	$343.75	-3.5%	+0.0%	+3.5%	+0.0%	-5.1%	-1.8%
Oct 13	Brookline Capital	Maintains	Buy → Buy	—	$2337.50	$2400.00	+2.7%	+9.6%	-2.7%	-2.8%	-2.3%	-1.1%
Jun 29	Litchfield Hills	Maintains	Buy → Buy	—	$1706.25	$1618.75	-5.1%	-4.4%	-2.3%	-0.8%	+16.2%	-3.4%

Data updated apr 24, 2026 10:56am · Source: massive.com